首页 | 官方网站   微博 | 高级检索  
     

埃索美拉唑三联与奥美拉唑三联疗法治疗Hp阳性十二指肠溃疡对比研究
引用本文:陈元鸿,王婉梅,王皓,李红艳.埃索美拉唑三联与奥美拉唑三联疗法治疗Hp阳性十二指肠溃疡对比研究[J].第一军医大学学报,2005,25(8):1045-1047.
作者姓名:陈元鸿  王婉梅  王皓  李红艳
作者单位:广东医学院附属医院消化内科,广东湛江524001
摘    要:目的比较埃索美拉唑三联与奥美拉唑三联疗法治疗幽门螺杆菌(Hp)阳性十二指肠球部溃疡的临床疗效。方法将104例经内镜诊断并检测证实Hp阳性的十二指肠球部溃疡患者随机分为两组。埃索美拉唑组(52例):埃索美托唑20mg+阿莫西林1g+克托霉素500mg,每日2次,共7d;奥美拉唑组(52例):奥美拉唑20mg+阿莫西林1g+克拉霉素500mg,每日2次,共7d。疗程结束4周后复查胃镜并检测Hp,观察腹痛缓解率、溃疡愈合率、Hp根除率及用药后的不良反应等。结果埃索美拉唑组第1天和第2天腹痛缓解率分别为34.6%和59、6%,高于奥美托唑组的17.3%和38.5%(P〈0.05)。埃索美托唑组和奥美拉唑组溃疡愈合率分别为92.3%和88.5%,Hp根除率分别为88.5%和82.7%,差异无显著性(P〉0.05)。两组用药后不良反应少,有较好的安全性。结论埃索美拉唑三联疗法治疗Hp阳性的十二指肠溃疡安全有效.腹痛缓解速度优于奥美拉唑三联疗法。

关 键 词:十二指肠球部溃疡  幽门螺杆菌  埃索美拉唑  奥美拉唑
文章编号:1000-2588(2005)08-1045-03
收稿时间:2005-04-18

Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection
Chen YuanHong;Wang WanMei;Wang Hao;Li GongYan.Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection[J].Journal of First Military Medical University,2005,25(8):1045-1047.
Authors:Chen YuanHong;Wang WanMei;Wang Hao;Li GongYan
Affiliation:Department of Gastroenterology, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China.
Abstract:OBJECTIVE: To investigate the effect of esomeprazole- and omeprazole-based triple therapy regimens in the treatment of duodenal ulcer with Helicobacter pylori (Hp) infection. METHODS: Totally 104 patients with duodenal ulcer and Hp infection were randomly divided into group A (52 cases) treated with esomeprazole (20 mg), amoxicillin (1000 mg) and clarithromycin (500 mg) twice daily and group B (52 cases) treated with omeprazole (20 mg), amoxicillin (1000 mg) and clarithromycin (500 mg) twice daily. The treatment lasted for 7 days, after which abdominal pain relief rate, ulcer healing rate and eradication rate of Hp as well as adverse effects of the medication were evaluated and compared. RESULTS: On the first and second days of medication, the abdominal pain relief rates were 34.6% and 59.6% respectively in group A, significantly higher than those in group B (17.3% and 38.5%, respectively, P<0.05). Ulcer healing rate and Hp eradication rate were 92.3% and 88.5 % in group A, and 88.5% and 82.7% in group B, showing no significant differences between the two groups (P>0.05). The adverse effects of the medication were rare in both groups without significant differences. CONCLUSION: Esomeprazole-based triple therapy may effectively eradicate Hp infection and promote duodenal ulcer healing with good tolerance, capable of achieving more speedy pain relief than omeprazole-based therapy.
Keywords:duodenal bulbar ulcer  Helicobacter pylori  esomeprazole  omeprazole
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号